rich777 casino OTTAWA - NDP Leader Jagmeet Singh says while he supports the Liberal plan to give Canadians a GST break during the holidays, he won’t back the $250 rebate proposal unless the government expands eligibility to the most vulnerable. The Liberals announced a plan last week to cut the federal sales tax on a raft of items such as toys and restaurant meals for two months, and to give $250 to more than 18.7 million Canadians in the spring. Speaking after a Canadian Labour Congress event in Ottawa, Singh said he’s open to passing the GST legislation, but the rebate needs to include seniors, students, people who are on disability benefits and those who were not able to work last year. Singh said he initially supported the idea because he thought the rebate cheques would go to anyone who earned under $150,000 last year. But the so-called working Canadians rebate will be sent to those who had an income, leaving out people Singh said need the help. A spokeswoman for Finance Minister Chrystia Freeland said it would be “categorically false” to say seniors and people with disabilities are excluded from the rebate. “In order to qualify, you just need to have made less than $150,000 in net income in 2023 and meet one of the three following criteria: received EI benefits, paid EI premiums or made CPP contributions,” press secretary Katherine Cuplinskas said in a statement. “Many, many seniors and Canadians with disabilities work.” The government intends to include the measures in the fall economic statement, which has not yet been introduced in the House of Commons. The proposed GST holiday would begin in mid-December, lasting for two months. It would remove the GST on prepared foods at grocery stores, some alcoholic drinks, children’s clothes and toys, Christmas trees, restaurant meals, books, video games and physical newspapers. A privilege debate has held up all government business in the House since late September, with the Conservatives pledging to continue a filibuster until the government hands over unredacted documents related to misspending at a green technology fund. The NDP said last week they had agreed to pause the privilege debate to pass the legislation to usher in the GST holiday. Singh said Tuesday that unless there are changes to the proposed legislation, he will not support pausing the debate. The Bloc Québécois is also pushing for the rebates to be sent to seniors and retirees. This report by The Canadian Press was first published Nov. 26, 2024.NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.69% during the forecast period. Rising global burden of diabetes is driving market growth, with a trend towards increasing growth opportunities in emerging markets. However, stringent regulatory guidelines poses a challenge.Key market players include Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Gastroparesis Drugs Market is witnessing significant growth due to the rising prevalence of Gastroparesis, a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx's tradipitant is a promising innovation, joining metoclopramide, metopimazine, deudomperidone, and prokinetic agents in symptom management. Diabetes, lifestyles (alcohol consumption, tobacco), and surgical procedures contribute to gastroparesis. Diabetic cases, especially those with autonomic neuropathy, are a major focus. Companies like Evoke Pharma and ANI Pharmaceuticals are leading the market with FDA-cleared drugs. GI symptoms like nausea, vomiting, and abdominal discomfort lead to nutrient absorption complications. Erythromycin and antiemetics are common treatments, but new clinical trials explore alternatives like Reglan. PubMed Central hosts numerous studies on gastroparesis, including Acute cholecystitis and Acute pancreatitis. Innovative drugs, such as those addressing blood sugar regulation, enteral nutrition, and feeding intolerance, are in development. Hospitals and specialized care centers offer surgical interventions for severe cases. Vendors in the gastrointestinal drugs market are expanding their businesses in emerging economies to tap into the growing number of individuals with undiagnosed and untreated gastrointestinal disorders. For instance, the incidence and prevalence of chronic gastrointestinal disorders in Asia , particularly in China and India , have been rising. To capitalize on this trend, companies are increasing their R&D efforts and manufacturing capacities in these regions. Abbott, for example, is expanding its R&D teams in Brazil , India , and China to enhance its product offerings and launch new solutions. This strategic expansion will create significant revenue opportunities and strengthen the market's growth trajectory. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! The Gastroparesis market faces challenges due to the complexities of the condition, which includes neurogastric disorders like Neurogastrx's tradipitant, metopimazine, deudomperidone, and metoclopramide. Diabetes, lifestyles factors such as alcohol consumption and tobacco use, and surgical procedures are common triggers. Innovative drugs are in development for symptom management, including Evoke Pharma's FDA-cleared prokinetic agent, and ANI Pharmaceuticals' deudomperidone. Diabetic gastroparesis cases are prevalent in hospitals, requiring specialized care. GI symptoms like nausea, vomiting, abdominal discomfort, and nutrient absorption complications hinder quality of life. Autonomic neuropathy, acute cholecystitis, and acute pancreatitis are associated conditions. Erythromycin and antiemetics like Reglan are commonly used, but clinical trials continue for new treatments. PubMed Central reports on the latest research, including studies on enteral nutrition and feeding intolerance. Regulatory authorities, such as the US FDA and the EMA, closely monitor and regulate the development and approval process of gastroparesis drugs. Safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions are key factors assessed during this process. Failure to meet these criteria may result in a complete response letter (CRL) or rejection. Applicants receiving a CRL must provide additional data to address regulatory concerns. Strict regulations ensure the highest standards of drug sterility and consistency. Discover how AI is revolutionizing market trends- Get your access now! This gastroparesis drugs market report extensively covers market segmentation by 1.1 Prokinetic agents 1.2 Antiemetics 1.3 Botulinum toxin injection 2.1 Idiopathic gastroparesis 2.2 Diabetic gastroparesis 2.3 Post-surgical gastroparesis 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Prokinetic agents- Prokinetic drugs play a significant role in managing gastroparesis, a condition characterized by delayed stomach emptying. These medications, such as metoclopramide and domperidone, are popular due to their ability to address the fundamental cause of the condition. While not all prokinetic agents produce a corresponding improvement in stomach emptying, they are effective in alleviating symptoms like nausea, vomiting, and early satiety. Other recent drugs, including ghrelin, motilin, 5-HT4 receptor agonists, and dopamine receptor agonists, are being studied for their potential in gastroparesis treatment. The use of prokinetic agents for symptoms like constipation, caused by decreased motility in the distal GI tract, also increases their demand and drives market growth during the forecast period. Ani Pharmaceuticals offers Reglan, a metoclopramide formulation, for gastroparesis treatment in the US. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Gastroparesis is a chronic condition characterized by delayed emptying of the stomach, leading to various digestive disruptions such as nausea, vomiting, and abdominal pain. Neurogastrx's tradipitant is a promising new drug for gastroparesis treatment, while metopimazine, deudomperidone, and metoclopramide are common antiemetics used for symptom management. Evoke Pharma and ANI Pharmaceuticals are among the companies involved in gastroparesis drug development. Diabetes, lifestyles including alcohol consumption and tobacco use, and certain medications like Erythromcin can trigger gastroparesis. Innovative drugs under clinical trials aim to address the underlying causes and improve patient outcomes. However, these drugs may carry risks such as liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis. Antiemetics like Reglan have been linked to Tardive Dyskinesia, a serious side effect. Clinical trials are ongoing to evaluate the safety and efficacy of new treatments for gastroparesis. Gastroparesis is a digestive disorder characterized by delayed emptying of the stomach. Neurogastrx's tradipitant is a promising innovative drug under development for gastroparesis treatment. Other prokinetic agents like metopimazine, deudomperidone, and metoclopramide are commonly used for symptom management. Evoke Pharma and ANI Pharmaceuticals are among the companies involved in gastroparesis drug development. Diabetes, lifestyles (alcohol consumption, tobacco use), and certain medications can trigger gastroparesis. Symptoms include nausea, vomiting, abdominal discomfort, and nutrient absorption complications. Diabetic gastroparesis is a common complication in diabetic cases. Hospitals and specialized care centers offer surgical interventions for severe cases, including FDA-cleared procedures. PubMed Central hosts numerous studies on gastroparesis, its causes, and potential treatments. Other conditions like Acute cholecystitis and Acute pancreatitis can also cause gastroparesis. Antiemetics like Erythromycin and Reglan are sometimes used to manage symptoms. Clinical trials are ongoing to explore new treatment options. Autonomic neuropathy is a potential cause of gastroparesis. Prokinetic agents help promote stomach contractions and hinder hindering digestion. Enteral nutrition and feeding intolerance are common complications. 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Drug Class Prokinetic Agents Antiemetics Botulinum Toxin Injection Disease Type Idiopathic Gastroparesis Diabetic Gastroparesis Post-surgical Gastroparesis Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio

Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif. , Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," said Warner Biddle , Chief Executive Officer of Kyverna. "Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases." Mr. Maziasz brings over 25 years of leadership and business experience across several leading biotechnology and large pharmaceutical companies. Mr. Maziasz most recently served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara, Mr. Maziasz led various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara, Mr. Maziasz was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Mr. Maziasz also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US, Europe , and Asia across business development, corporate strategy, finance, and commercial functions. Ms. Bauer brings more than 25 years of experience in global human resources leadership to Kyverna, having served most recently as Global Head of Human Resources at Kite, a Gilead Company, where she oversaw all HR strategy and operations during a period of hypergrowth and global expansion which strengthened the company's leadership position in cell therapy. Prior to this role, she served as the Global Head of HR for the Entertainment Division at Riot Games where she worked directly with the founders to build an Entertainment Studio separate from the core gaming business. Ms. Bauer has also held various HR leadership roles at companies such as Netflix, Amgen, Gartner and Novo Nordisk. Ms. Rossin brings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affairs at Kite, where she was responsible for leading corporate, product and employee communications in addition to patient advocacy. Prior to this role, she served as Vice President, Global Head of Communications at Innate Pharma, an oncology-focused biotech company, where she led both corporate and financial communications. Ms. Rossin also spent more than 12 years at AstraZeneca/MedImmune, where she held multiple U.S. and global communications roles for key therapeutic areas across AstraZeneca's portfolio before serving as the Head of Corporate Affairs at MedImmune, the global biologics research and development arm of AstraZeneca. Before joining AstraZeneca, she held various positions at global public relations agencies working with corporate and healthcare related clients. Inducement Grant In connection with the appointment of Mr. Maziasz as Kyverna's Chief Business Officer, on December 9, 2024 , Kyverna granted Mr. Maziasz an option to purchase 350,000 shares of its common stock (Option). The Option was granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors on September 14, 2024 , and was granted as an inducement material to Mr. Maziasz's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option was $4.86 , the closing price of Kyverna's common stock on December 9, 2024 , the date of grant. The Option will vest over four years, with 25% of the total number of shares subject to the Option vesting on the one-year anniversary of Mr. Maziasz's appointment and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Maziasz's continued service to Kyverna on each vesting date. Kyverna is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com . Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of the clinical outcomes from the ongoing clinical programs; the potential impact of the new data on the treatment efficacy and safety profile of KYV-101; the potential that the results of the ongoing trials could drastically change the treatment landscape for the targeted autoimmune diseases; Kyverna's goals to develop certain paradigm-shifting treatment options; the potential for KYV-101 to provide durable, immunosuppressant-free remission for autoimmune disease patients; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: Investors: InvestorRelations@kyvernatx.com Media: media@kyvernatx.com View original content to download multimedia: https://www.prnewswire.com/news-releases/kyverna-therapeutics-strengthens-leadership-team-to-accelerate-next-phase-of-growth-302331659.html SOURCE Kyverna TherapeuticsCould Elon Musk X-ify MSNBC? Don’t Bet On It

Arguments over whether Luigi Mangione is a 'hero' offer glimpse into unusual American moment

Hunter, Jeanty give Heisman ceremony a different vibeAlicia Graf Mack, Renowned Dancer, Educator, and Institutional Leader, Appointed Artistic Director of AileyNone